Pooled human plasma
Phase 3Small molecule
Pooled human plasma is one of 39 small molecule programs targeting Spinal Fusion. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Spinal Fusion
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Marcaine
IInnocoll
Approved
Toradol
JJavelin Pharmaceuticals
Approved
Decadron
AAspen Global Incorporated
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Vivarin
HHikma Pharmaceuticals LLC
Approved
Duragesic
CCephalon
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pooled human plasma. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TTurku University Hospital